Safety, tolerability, PK [pharmacokinetics] and PD [pharmacodynamics] of LY2405319 after multiple subcutaneous injections in subjects with type 2 diabetes

Trial Profile

Safety, tolerability, PK [pharmacokinetics] and PD [pharmacodynamics] of LY2405319 after multiple subcutaneous injections in subjects with type 2 diabetes

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Sep 2010

At a glance

  • Drugs LY 2405319 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Sep 2008 Status changed from not yet recruiting to recruiting.
    • 12 Aug 2008 The planned initiation date for this trial is now August 2008 accoring to clincialtrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top